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Abstract 
Product development of ophthalmic preparations has received 
considerable attention in the last few years. With the increasing 
emphasis on their sterility, some of the differences between them 
and parenteral preparations are becoming less evident. Both 
classes of preparations employ similar added substances and 
manufacturing procedures. The successful formulation of poorly 
water-soluble drugs is one of the major problems in 
pharmaceutical manufacturing. Poorly water-soluble drugs, such 
as indomethacin, may show low and erratic oral bioavailability 
due to poor dissolution of the drug in the fluids of the 
gastrointestinal tract. Indomethacin is a water insoluble drug, so 
problems of formulating an aqueous eye-drop are well known. 
Moreover, unstability of Indomethacin aqueous preparations is 
also a great challenge. In this research work, considering 
pharmacological importance of drug Indomethacin, we tried to 
overcome the problem of poor water solubility by making a salt of 
it and thus formulating an aqueous ophthalmic preparation. 
Keywords: ophthalmic preparation, indomethacin salt, aqueous 
eye drops, poor water soluble drugs. 
 
 
 
Introduction 
Absorption of drugs into the eye requires good 
pre-corneal penetration and prolonged contact 
time with corneal tissues. Ideally, the formulation 
should be able to sustain drug release and to 
maintain contact with the eye for extended 
periods of time. The extent of absorption into the 
eye is severely limited by the physiological 
constraints such as reflex tearing and blinking. 
Further, drug loss occurs due to tear turnover, 
solution drainage by gravity and binding of drugs 
to proteins and other components of tear. As a 
result, typically only 1-2% of the instilled drug is  
 
 
bioavailable. In recent times, great emphasis has 
been placed on the importance of formulation 
with the recognition that they can significantly 
influence the physiologic availability of drugs. It 
is becoming increasingly evident that the rate of 
dissolution or release of the drug from the 
formulation is of paramount importance and that 
even minor changes unknowingly can greatly 
influence this property in some cases. In dealing 
with the formulation of new products, as the 
variety and complexity of materials and 
techniques have increased, it has become 
necessary to apply the best research methods and 
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tools, in order to develop, produce and control the 
potent, stable and effective dosage forms.1, 2 
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
are widely used agents that despite chemically 
heterogeneity, share similar therapeutic properties 
and adverse effects. Topical ophthalmic NSAIDs 
are limited to the relatively water soluble 
phenylacetic and phenylalkanoic acids as well as 
indole derivatives, which are more suitable for 
ophthalmic use. Topical ophthalmic NSAIDs are 
commonly used in the treatment of post-operative 
inflammation following cataract extraction and 
various surgical refractive procedures. They are 
also used in the prevention and treatment of 
cystoid macular oedema and for the treatment of 
allergic conjunctivitis. Local irritant effects of 
topical ophthalmic NSAIDs include conjunctival 
hyperaemia, burning, stinging and comeal 
anaesthesia. A more serious complication 
involves the association of topical ophthalmic 
NSAIDs with indolent corneal ulceration and 
full-thickness corneal melts. In general, 
ophthalmic NSAIDs may be used safely with 
other ophthalmic pharmaceuticals. Until clinical 
evidence dictates otherwise, data supporting 
theories of potential pharmacodynamic 
mechanisms of NSAID injury do not alter the 
favorable benefit-risk ratio of ophthalmic NSAID 
use when employed in an appropriate and 
judicious manner.3-8 
 
Materials and Methods 
Drug Indomethacin was generously gifted by 
Alchem Laboratories, Bombay. Excipients were 
obtained from commercial sources and were of 
analytical grade. 
 
Determination of solubility of indomethacin 
Indomethacin is a low soluble drug (specifically 
in water). Its solubility was determined in 
following solvents and their combinations and 
also in presence of solubilizing agents, by placing 
an excess quantity of drug in a vial along with the 
solvent. The tightly closed vials were then 
agitated for 24 hr at 30º C + 2º C. The solutions 
were filtered through a 0.45μm filter and the 
filtrate was analyzed for drug content on a UV / 
Vis spectrophotometer (Jasco – V550) after 
appropriate dilutions.  
Preparation of sodium salt of indomethacin 
After trying different solvents and solubilizing 
agents, it was clear that for formulating eye 
drops, it was not possible to achieve a target of 
10-mg/ml concentration of indomethacin in 
desired aqueous medium. So, Indomethacin was 
converted into its sodium salt for formulation of 
aqueous eye drops. Following method was tried 
for the preparation of indomethacin sodium: 50-
ml methanol was taken in a round bottom flask 
kept on water bath. Accurately weighed 5g 
indomethacin was added to it slowly at 50º C 
with continuous stirring until a clear solution was 
obtained. Sodium bicarbonate solution (in 1:1 
molar ratio with indomethacin) was added to the 
above solution drop wise with continuous 
stirring. The reaction was continued at room 
temperature with stirring at 350 rpm for 2 hrs. 
The solvent was evaporated by Buchi’s Rota 
vapour at 35º C. Solid residue was washed with 
diethyl ether and filtered indomethacin sodium so 
obtained was dried overnight under vacuum and 
weighed. Same method was again tried using 
sodium methoxide and sodium hydroxide in place 
of sodium bicarbonate. Sodium salt prepared by 
all the three methods was characterized. 
Characterization of prepared Indomethacin 
sodium 
On the basis of data reported in various 
pharmacopoeias, indomethacin sodium prepared 
by above three methods was analyzed and 
characterized by following parameters. 
Solubility: Solubility of prepared indomethacin 
sodium was determined in water and methanol at 
room temperature. The results are recorded in 
table no.1. 
pH: Indomethacin is a weak acidic drug. 
Conversion of indomethacin base into its sodium 
salt will shift the pH of solution towards alkaline 
side. The pH of 1% solution of prepared 
indomethacin sodium is given in table no.1. 
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Melting point: Melting point of prepared 
indomethacin sodium was determined by melting 
point apparatus. As it is a metallic salt, its melting 
point should be higher than the base. Normally, a 
salt does not give a sharp melting point because it 
will char over a wide range of temperature. 
Melting points are` given in table no.1. 
 
Table no. 1 Solubility, pH and melting points of 
prepared indomethacin sodium 
 Method of 
prepa-
ration 
Solubility 
in water 
Methanol pH of 1% 
solution 
Melting 
Point 
Using 
sodium 
methoxide  
Not 
soluble 
Soluble 7 – 7.5 155º - 
160º C 
Using 
sodium 
hydroxide 
Soluble Soluble 9 – 9.5 260º - 
270º C 
Using 
sodium 
bicarbonate 
Soluble Soluble 8.5 – 9.0 215º - 
220º C 
 
UV/Visible spectroscopy:  
The UV spectra of indomethacin base and 
prepared indomethacin sodium were obtained by 
scanning solutions of 20 ppm concentration in 
methanol in the range of 200-400 nm wavelength 
on Jasco V-550 UV / Vis spectrophotometer. An 
overlay of indomethacin sodium prepared using 
sodium bicarbonate over indomethacin base is 
shown in fig. no.1 
 
Fig.no.1 An overlay of sodium indomethacin 
over indomethacin base. 
Differential scanning calorimetry:  
The DSC thermogrames are obtained by placing 
the sample in a calorimeter with a programmed 
temperature device, so that the temperature will 
increase from 55.00˚C to 340˚C at 10.00˚ C / 
min. Sample was held for 1.0 min at 55.00˚C. 
The calorimeter also contains a control cell with a 
known heat capacity. The heat flowing into two 
cells is monitored and balanced to get a 
“baseline”. When, there is a thermal event in the 
sample cell (e.g., melting), there will be an 
endotherm, which will be registered as a peak, 
which falls back to baseline when the event is 
over. The area under the peak can be converted to 
calories or joules. 
The DSC thermograms of indomethacin and 
prepared indomethacin sodium are shown in fig. 
no.2 and 3. 
 
Fig. no. 2 DSC thermogram of indomethacin 
 
Fig. no. 3 DSC thermogram of indomethacin 
sodium 
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IR spectroscopy: 
The infrared absorption spectrum of 
indomethacin and prepared indomethacin sodium 
were recorded between the wavelengths of 2000 
to 400 cm-1 on a Hyper IR, Shimadzu standard 
detector in 1% KBr. The Peaks of indomethacin 
base were compared with those of indomethacin 
sodium. 
Potentiometric analysis: 
Sample of prepared indomethacin sodium was 
analyzed quantitatively by potentiometric 
titration using Titrando 808-auto titre. 
First, a solution of indomethacin sodium was 
prepared by dissolving 200-mg sample in 50-ml 
methanol. This solution was titrated against 0.1M 
NaOH to check whether there is any free base left 
in the sample. But, since a straight curve without 
any peaks was obtained, this further confirms 
that, there was no reaction between sample 
solution and NaOH solution. 
Same sample solution was again titrated 
potentiometrically with 0.1 M HCl to calculate 
the quantity of indomethacin sodium present in 
the sample. The titration graphs are shown in fig. 
no.4 
 
Fig. no. 4 Titration curve of indomethacin 
sodium against 0.1 N HCl 
 
Preformulation studies 
Preformulation studies mainly focus on those 
physicochemical properties of the compound that 
could affect drug performance and development 
of an efficacious dosage form. A thorough 
understanding of these properties may ultimately 
provide a rationale for formulation design.  
Solubility of prepared Indomethacin sodium 
at different pH: 
Phosphate buffers of different pH in the range 
from 5 to 9 pH were prepared. The solubility of 
prepared indomethacin sodium in these buffers 
was determined by adding the drug into the 
buffer solution gradually in a test tube and after 
shaking observing the solubility visually. 
Stability of Indomethacin sodium at different 
pH: 
After finding out that Indomethacin sodium is 
more soluble at pH above 6, its stability at pH 
between 6 to 9 was determined by keeping 1% 
solutions in phosphate buffers of pH 6 to 9 for 15 
days at room temperature. Samples were taken 
from each solution at regular interval and 
concentration of sodium indomethacin was 
estimated spectrophotometrically using UV/Vis 
spectrophotometer Jasco V-550 after appropriate 
dilution with methanol. The samples were also 
visually checked for any sign of physical 
unstability in this duration. The results are given 
in a graph of pH against concentration is shown 
in fig. no.5. 
Effect of pH on stability of IND-
Sodium solution
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Fig. no. 5 Effect of pH on stability of 
Indomethacin sodium solution 
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Compatibility Studies: 
1% solution of indomethacin sodium was 
prepared in phosphate buffer. The pH was 
maintained at 6.8. 5 ml of this solution was taken 
in glass vials and mixed with 0.9% sodium 
chloride, tween 80 (1% v/v), benzyl alcohol (1% 
v/v), benzalkonium chloride (0.025%w/v), 
chlorobutanol (0.5% w/v), phenyl mercuric 
nitrate (0.004%w/v), propyl paraben 
(0.015%w/v) and methyl paraben (0.05%w/v) 
respectively as per IIG. The glass vials were 
stoppered with rubber stopper, sealed and stored 
at different storage conditions to find out physical 
and chemical compatibility of indomethacin 
sodium with excipients. A sample of plain 
indomethacin sodium without any excipient was 
kept as the control. 
Physical compatibility: 
Vials were checked at regular intervals for 
clarity, color change etc. 
Chemical compatibility:  
Since, there was some turbidity due to 
precipitation in drug solution containing benzyl 
alcohol; samples of these solutions were 
discarded. Other solutions were taken for 
chemical compatibility studies. The above drug 
solutions kept under different storage conditions 
were analyzed for drug content at 320 nm on a 
UV / Vis Jasco V-550 spectrophotometer after 
appropriate dilutions with methanol. 
Absorbance’s of sample solutions were compared 
with that of control samples.  (Initial drug content 
was 100.80%). 
Selection of sterilization method  
Membrane filter of 0.2-µm porosity was used for 
sterilization by filtration in μm aseptic area. The 
suitability of both methods of sterilization in the 
present study was tested by determining drug 
content of representative eye drop formulation of 
indomethacin sodium (aqueous based) before and 
after subjecting to sterilization by the respective 
method.  
 Aqueous base solutions were prepared with 1 % 
drug and other excipients filled in vials and 
sealed. These vials were autoclaved for 20 
minutes. In some other vials, solutions were filled 
by filtration through 0.2μm Millex, Millipore 
filter.  
Formulation of indomethacin eye-drops 
On the basis of results obtained during 
preformulation studies following formulations of 
Indomethacin eye-drops were devised. 
Table no. 2 Formulation of indomethacin sodium aqueous drops 
S. No. Formu-
lation 
Code 
Ingredients Quantity Application 
1 INDOA1 Indomethacin 
sodium 
(equi.to) 
Tween-80 
Methyl 
Paraben 
Sodium 
chloride 
(equi.to) 
Phosphate 
buffer in WFI 
1% (w/v) 
base 
1% (v/v) 
0.05% (v/v) 
0.9% (w/v) 
q.s to 100% 
(v/v) 
Drug  
Solubiliser  
Preservative  
Tonicity 
modifier 
Buffering 
agent & 
vehicle 
2 INDOA2 Indomethacin 
sodium 
(equi.to) 
Tween-80 
BKC 
Sodium 
chloride 
(equi.to) 
Phosphate 
buffer in WFI  
1% (w/v) 
base 
1% (v/v) 
0.025% 
(v/v) 
0.9% (w/v) 
q.s to 100% 
(v/v) 
Drug  
Solubiliser  
Preservative  
Tonicity 
modifier 
Buffering 
agent & 
vehicle 
3 INDOA 3 Indomethacin 
sodium 
(equi.to) 
Tween-80 
Chlorobutanol 
Sodium 
chloride 
(equi.to) 
Phosphate 
buffer in WFI  
1% (w/v) 
base 
1% (v/v) 
0.5% (v/v) 
0.9% (w/v) 
q.s to 100% 
(v/v) 
Drug  
Solubiliser  
Preservative  
Tonicity 
modifier 
Buffering 
agent & 
vehicle 
4 INDOA4 Indomethacin 
sodium 
(equi.to) 
Tween-80 
Phenyl 
1% (w/v) 
base 
1% (v/v) 
0.004% 
Drug  
Solubiliser  
Preservative  
Tonicity 
 
 
145
Kulkarni et al. International Journal of Drug Delivery 3 (2011) 141-148 
 
mercuric 
nitrate  
Sodium 
chloride 
(equi.to) 
Phosphate 
buffer in WFI  
(v/v) 
0.9% (w/v) 
q.s to 100% 
(v/v) 
modifier 
Buffering 
agent & 
vehicle 
 
Formulation method–  
Initially isotonic saline phosphate buffer was 
prepared in a 250-ml flask using water for 
injection. Weighed quantity of indomethacin 
sodium was dissolved in it. Preservative was 
dissolved in a little WFI separately with the help 
of heating at 60-80˚C. Tween 80 and preservative 
solutions were added to the drug solution with 
proper stirring. The formulations were filtered 
through 0.2µm filters in aseptic area and filled in 
sterilized vials and sealed. pH of all the 
formulations adjusted between 6.8 and 7.0. 
Vials, glassware’s and other equipments used in 
the preparation of eye drops were sterilized in hot 
air oven at 250˚C for 2 hr and the WFI was 
freshly prepared. Preparation of formulation, 
filtration, filling and sealing were all completed 
in class 10,000 area under the protection of 
HEPA-filtered laminar flow. 
Packaging of products: 
Since indomethacin is reported to be a light 
sensitive drug , so 10 ml, 20 mm USP type–I flint 
glass vials were used as containers. For closing 
these vials, 20-mm Grey bromo-butyl slotted 
rubber stoppers were used. These packaging 
materials were tested as per USP.  
Evaluation of formulated products 
Assay Procedure  
1 ml of each formulation was accurately taken 
and transferred to a 100 ml volumetric flask. It 
was diluted to 100 ml methanol. 10 ml of this 
was again diluted with solvent to 100 ml. Two 
dilutions of each sample were prepared at a time 
for cross check. Absorbance of each dilution was 
measured at 320 nm on a Jasco–V-550, UV/Vis 
spectrophotometer. The results are recorded in 
table no. 3 
Table no. 3. Assay of formulated indomethacin 
eye drops 
Formulation code Concentration 
INDAD1 10.24 mg/ml 
INDAD2 10.05 mg/ml 
INDAD3 10.25 mg/ml 
INDAD4 10.06 mg/ml 
 
Sterility testing 
Prepared indomethacin eye drops were tested for 
sterility as per USP. The test was done by direct 
inoculation method. Fluid Thioglycollate was 
used for aerobes and facultative anaerobes while 
Soyabean Casein Digest Broth was used for 
aerobes and fungi. Test mixtures were incubated 
in culture tubes and media was examined for 
microbial growth. Incubation was continued for a 
total of 14 days from the original incubation at 
32.5 + 2.5ºC. Control samples of aerobes, 
anaerobes and fungi were prepared in both the 
medium. All the formulations passed test of 
sterility. 
Stability Study of formulated indomethacin 
eye drops 
The formulated products were subjected to 
stability studies at different storage conditions as 
per ICH guidelines.  The sealed vials containing 
different formulations were kept in the 
temperature / humidity control ovens 
(Newtronics). Some vials were also kept in 
inverted position to check any interaction 
between rubber closure and formulation. The 
drug content of each formulation was determined 
after different time intervals and percent residual 
drug was calculated. 
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Table no. 4. Stability study protocol for formulated 
products 
S.No. Test  Storage 
Conditi
on 
Period Limits 
during 
stability 
A Physical 
test 
Appearance  
pH 
2-8˚C 
25˚C / 
60% RH 
30˚C / 
65% RH 
Initial 
7days 
15 days 
- 
- 
B Chemical 
test assay 
40˚C / 
75% RH 
1 month 
3 months 
 
5% 
change 
 
Results 
From the solubility studies, it is clear that we 
cannot prepare a 1% solution of indomethacin in 
water using any of the above co-solvents or 
solubilizing agents. Since, indomethacin sodium 
prepared by sodium bicarbonate was showing 
expected results like solubility, pH, melting point, 
λmax, and UV spectra, it was selected for further 
studies. The thermograms clearly indicate a shift 
of endotherm towards higher side in case of 
indomethacin sodium as compared to that of 
indomethacin base. The thermogram of 
indomethacin sodium did not give a sharp peak as 
the indomethacin base. Also, there was no other 
peak in the thermogram of prepared 
indomethacin sodium except a peak of solvent, 
which confirms that the sodium salt has been 
formed. 
The peaks of IR spectra of indomethacin sodium 
do not overlap the peaks of IR spectra of 
indomethacin base. So, two spectrums do not 
comply with each other and there is a significant 
shift that indicates that there is no free base 
present in the sample and it has been converted 
into indomethacin sodium. Assay of prepared 
indomethacin sodium was found to be 100.65%, 
which shows that the base indomethacin was 
fully converted into its sodium salt. It was 
observed that indomethacin sodium is more 
soluble in pH range of 6 to 9. Below pH 6, there 
was an incompatibility due to precipitation of free 
indomethacin base. Observations showed that 
solution of indomethacin sodium was most stable 
in the pH range of 6.5 to 7.5. 
On the basis of compatibility studies these studies 
it could be inferred that benzyl alcohol is not 
suitable for indomethacin sodium eye drop 
formulation. Other excipients tested in the 
compatibility studied, can be used in the product 
development of indomethacin eye drops. On the 
basis of sterility studies it was decided that so 
both the methods can be used for sterilization of 
eye drops in the present studies. 
Sodium and potassium salts are most simple to 
prepare. Some stability problems in aqueous 
preparations and during sterilization may arise 
but still various research works is going on in this 
field. Studies are in the stage of clinical trials and 
many have already applied for FDA registration. 
As we have seen in this project, sod. IND is 
stable at a neutral pH, which is easily tolerable by 
patients. Moreover, it is very soluble in water and 
buffer, so can be easily stabilized by using other 
additives like viscosity importing agent, 
solubiliser, antioxidants etc. Without using all 
this excipients also, salt was stable in aqueous 
solution at accelerated temperature / humidity 
conditions. Anti-inflammatory activity of Sod. 
IND has been already studied and is equal to 
indomethacin base. 
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